Highly Well Differentiated Hepatocellular Carcinoma and Benign Hepatocellular Lesions

2003 ◽  
Vol 47 (1) ◽  
pp. 16-26 ◽  
Author(s):  
Aileen Wee ◽  
Barbro Nilsson
Keyword(s):  
Hepatocellular Carcinoma ◽  
Well Differentiated

scholarly journals Hepatic Epithelioid Hemangioendothelioma Presenting Synchronously with Hepatocellular Carcinoma

2021 ◽  
pp. 344-351
Author(s):  
Hiroki Kanno ◽  
Toshihiro Sato ◽  
Ryuta Midorikawa ◽  
Satoki Kojima ◽  
Shogo Fukutomi ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Carbohydrate Antigen ◽  
Epithelioid Hemangioendothelioma ◽  
Arterial Phase ◽  
Rapid Progression ◽  
Imaging Findings ◽  
Liver Segment ◽  
Contrast Enhanced ◽  
Well Differentiated ◽  
Enhanced Computed Tomography

Hepatic epithelioid hemangioendothelioma (EHE) is a rare malignant tumor with unknown pathogenesis. Herein, we report a case of a hepatic EHE presenting synchronously with a hepatocellular carcinoma (HCC). To the best of our knowledge, this is the second case report of synchronous hepatic EHE and HCC. An 84-year-old man presented with back pain. During examination, a tumor in liver segment 3 was coincidentally detected. Tumor marker (carbohydrate antigen 19-9, alpha-fetoprotein, and protein induced by vitamin K absence or antagonist-II) levels were elevated. Contrast-enhanced computed tomography revealed perinodular enhancement in the arterial and portal phases. Another tumor was detected in liver segment 2, which was homogeneously enhanced in the arterial phase, followed by washout in the portal and late phases. Based on these imaging findings, we diagnosed the tumor in segment 3 as a solitary cholangiocellular carcinoma and the tumor in segment 2 as a solitary HCC. Lateral sectionectomy of the liver was performed. Microscopically, spindle-shaped and epithelioid cells were present in the tumor in segment 3. On immunohistochemistry, the tumor cells were positive for CD31 and CD34, focally positive for D2-40, and negative for AE1/AE3. Therefore, the tumor in segment 3 was ultimately diagnosed as an EHE and the tumor in segment 2 as a well-differentiated HCC. Preoperative diagnosis of EHE is difficult owing to the lack of specific findings. Intratumoral calcification, halo sign, and lollipop sign are occasionally found in EHE and are useful imaging findings for diagnosis. Clinical behavior is unpredictable, ranging from indolent growth to rapid progression. Clinical or pathological predictors of the course of EHE are urgently required.

Pelioid-type well-differentiated hepatocellular carcinoma in a patient with a history of taking oral contraceptives: Report of a case

Surgery Today ◽  
2011 ◽  
Vol 41 (9) ◽  
pp. 1270-1274 ◽  
Author(s):  
Naoya Ikeda ◽  
Kuniyuki Oka ◽  
Nobuo Yonekawa ◽  
Hideya Takaku ◽  
Toshishige Suzuki ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Oral Contraceptives ◽  
History Of ◽  
Well Differentiated

scholarly journals Fibrolamellar Carcinoma: A Multimodal Approach

2020 ◽  
Vol 27 (6) ◽  
pp. 429-433
Author(s):  
João Vasco Barreira ◽  
Nádia Silva ◽  
Anuraj Parmanande ◽  
Manuel Rocha ◽  
João S. Coelho ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Viral Hepatitis ◽  
Cancer Patients ◽  
Clinical Presentation ◽  
Multidisciplinary Teams ◽  
Multimodal Approach ◽  
Fibrolamellar Hepatocellular Carcinoma ◽  
Serum Alpha Fetoprotein ◽  
Fibrolamellar Carcinoma ◽  
Well Differentiated

Fibrolamellar carcinoma is a rare variant of hepatocellular carcinoma not associated with cirrhosis or viral hepatitis. Serum alpha-fetoprotein levels are usually normal; the histology is of a well-differentiated tumor, and the staging is the same as for hepatocellular carcinoma. We describe the case of a female patient in her 4th decade of life with a diagnosis of fibrolamellar hepatocellular carcinoma with a multimodal approach. The rare incidence of this cancer and its unusual clinical presentation justifies reporting this case and highlights the importance of multidisciplinary teams in the treatment of cancer patients.

scholarly journals Non-islet-cell tumour hypoglycaemia in a cat with hepatocellular carcinoma

2019 ◽  
Vol 5 (1) ◽  
pp. 205511691985612
Author(s):  
Alexandra Guillen ◽  
Lorenzo Ressel ◽  
Riccardo Finotello ◽  
Alexander J German ◽  
Alistair Freeman ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Islet Cell ◽  
Abdominal Mass ◽  
Reference Interval ◽  
Serum Glucose ◽  
Cell Tumour ◽  
Surgical Removal ◽  
Islet Cell Tumour ◽  
Insulin Growth Factor ◽  
Well Differentiated

Case summary An 11-year-old male neutered domestic shorthair cat presented with behavioural changes. Physical examination revealed bradycardia and a cranial abdominal mass. The cat was persistently hypoglycaemic (1.2 mmol/l; reference interval [RI] 3.5–5.5 mmol/l) with decreased fructosamine concentration suggesting chronic hypoglycaemia, and decreased insulin concentration excluding insulinoma. Alanine aminotransferase activity was markedly increased (1219.31 U/l; RI 15–60 U/l). On staging CT a large, multilobulated hepatic mass was identified, with no evidence of metastatic disease. After surgical removal serum glucose concentration and heart rate quickly returned to within the RIs. Histopathology was consistent with a solid-to-trabecular, well-differentiated, hepatocellular carcinoma. There was no recurrence of signs or mass during 8 months of follow-up, and the cat was still alive 20 months after surgery. Relevance and novel information Non-islet-cell tumour hypoglycaemia (NICTH) is a rare but life-threatening paraneoplastic syndrome. In humans, hepatocellular carcinoma is the most common epithelial tumour causing NICTH, but these are uncommon in cats, and associated paraneoplastic hypoglycaemia has not been reported. Possible mechanisms include aberrant secretion of big insulin growth factor 2; however, this could not be confirmed. NICTH should be considered in the differential diagnosis of cats with persistent hypoglycaemia.

Sign in / Sign up

Export Citation Format

Share Document